Long-term functional outcomes after treatment for localized prostate cancer

New England Journal of Medicine

Volumn 368, Issue 5, 2013, Pages 436-445

  Resnick, Matthew J ^a,d   Koyama, Tatsuki ^b   Fan, Kang Hsien ^b   Albertsen, Peter C ^e   Goodman, Michael ^f   Hamilton, Ann S ^g   Hoffman, Richard M ^h   Potosky, Arnold L ⁱ   Stanford, Janet L ^j   Stroup, Antoinette M ^k   Lawrence Van Horn, R ^c   Penson, David F ^a,d  

^a Center for Outcomes Research   (United States)

^b Clinical Center   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

^k UNIVERSITY OF UTAH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DEFECATION URGENCY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INTESTINAL DYSMOTILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; URINE INCONTINENCE;

EID: 84873050980     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1209978     Document Type: Article

References (33)

1. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011;117:1429-37.
2. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
3. Birkhahn M, Penson DF, Cai J, et al. Long-term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy. BJU Int 2011;108:660-4.
4. Song L, Chen RC, Bensen JT, et al. Who makes the decision regarding the treatment of clinically localized prostate cancer - the patient or physician? Results from a population-based study. Cancer 2012 July 11 (Epub ahead of print).
5. Zeliadt SB, Moinpour CM, Blough DK, et al. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care 2010;16(5):e121-e130.
6. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007;25:3576-81.
7. Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 1999;91:1719-24.
8. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582-92.
9. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004;96:1358-67.
10. Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL. Validation study of retrospective recall of disease-targeted function: results from the Prostate Cancer Outcomes Study. Med Care 2000;38:847-57.
11. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy: the national Medicare experience: 1988-1990 (updated June 1993). Urology 1993;42:622-9.
12. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36:1002-12.
13. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905.
14. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010;76:1245-50.
15. Reeve BB, Potosky AL, Willis GB. Should function and bother be measured and reported separately for prostate cancer quality-of-life domains? Urology 2006;68:599-603.
16. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
17. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
18. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2012 (http://www.R-project.org).
19. Lumley T. Analysis of complex survey samples. J Stat Softw 2004;9:1-19.
20. Idem. Analysis of complex survey samples: R package version 3.28-2. Vienna: R Foundation for Statistical Computing, 2012.
21. Ihrig A, Keller M, Hartmann M, et al. Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapy. BJU Int 2011;108:1274-8.
22. Sommers BD, Beard CJ, D'Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008;113:2058-67.
23. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-8.
24. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.
25. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009;101:888-92.
26. Rice K, Hudak J, Peay K, et al. Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology 2010;76:1231-8.
27. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010;183:2206-12.
28. Knight SJ, Latini DM, Hart SL, et al. Education predicts quality of life among men with prostate cancer cared for in the Department of Veterans Affairs: a longitudinal quality of life analysis from CaPSURE. Cancer 2007;109:1769-76.
29. Pardo Y, Guedea F, Aguiló F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010;28:4687-96. [Erratum, J Clin Oncol 2011;29:779.]
30. Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011;12:891-9.
31. Litwin MS. Health related quality of life in older men without prostate cancer. J Urol 1999;161:1180-4.
32. Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 2004;101:2011-9.
33. Taylor KL, Luta G, Miller AB, et al. Long-term disease-specific functioning among prostate cancer survivors and non-cancer controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol 2012;30:2768-75.